1
H and 13 C NMR spectra were recorded on a Bruker DRX-300, and inverse-detected heteronuclear correlations were measured using HMQC and HMBC on a Bruker Avance 500 with TMS as the internal standard. UV and IR data were recorded on a Shimadzu UV-1800 and a JASCO 100 IR spectrometers. For the isolation, analytical TLC was performed on pre-coated Merck F 254 silica gel plates and visualized by spraying with 10%-H 2 SO 4 followed by heating. Column chromatography was conducted using Merck kiesel gel 
Extraction and isolation
The air-dried whole G. hederecea plant (7.4 kg) was extracted with ethanol (2 × 60 L) for 3 days at room temperature. The filtrated ethanol soluble extract (420 g) was concentrated in vacuo and then suspended in distilled water (2 L). The aqueous residue was partitioned and concentrated successively with hexane (2×2 L), ethyl acetate (2×2.5 L), and butanol (2×2 L) to obtain a hexane soluble fraction (GH, 45 g), ethyl acetate soluble fraction (GE, 41 g), and a butanol soluble fraction (GB, 51 g). Since the ethyl acetate soluble fraction exhibited the greatest inhibition activity on human cancer cell lines, it was subjected to silica gel column chromatography (10×20 cm) and eluted with a CHCl 3 :MeOH gradient (300:1 to 1:1, 600 mL). Thin layer chromatography (TLC) resulted in eight (A-H) fractions. Obtained from bioactivity-guided fractionation, fraction B was further chromatographed on a silica gel column chromatography (4×25 cm) using CHCl 3 :MeOH gradient (250:1 to 1:1, 450 mL) and purified by preparative high performance liquid chromatography (prep-HPLC) with MeOH:H 2 O (50:50, 700 mL) to afford 1 (20 mg, 97%), 4 (17 mg, 96%), and 6 (7 mg 96%). Fraction C was rechromatographed over silica gel column chromatography (4×25 cm) using CHCl 3 :MeOH gradient (250:1 to 1:1, 550 mL) and purified by prep-HPLC with MeOH:H 2 O (50:50, 600 mL) to obtain 2 (20 mg, 94%), 3 (7 mg, 93%), 5 (29 mg, 94%), and 7 (5 mg, 96%). The mean of percentages is the purity of compounds.
Biological assays
For the assessment of the cytotoxicity in human cancer cell lines, MDA-MB-231(breast), HCT116 (colon), SW620 (colon), and DU145 (prostate) cell lines were used for the MTT assay. Cells were grown in RPMI 1640 media at 37°C under a 5% CO 2 incubator into a 96-well plate for 24h. The compounds were prepared by dissolution in DMSO, and the cells were treated in serum free RPMI 1640 for 24 h. 3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide (MTT) solution at 5 mg/mL was dissolved in PBS, and it was added to each of the 96 wells for 1h at 37°C. Then, each of the cells was dissolved in DMSO and read at 490 nm using a microplate reader. Doxorubicin (Sigma, 98%) was used as a positive control. 
